LU92024I2 - Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR) - Google Patents

Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)

Info

Publication number: LU92024I2
Authority: LU; Luxembourg
Prior art keywords: signifor; pasireotide; pharmaceutically acceptable; acceptable derivatives; derivatives
Prior art date: 2000-08-01

Application number

LU92024C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-01

Filing date

2012-06-20

Publication date

2012-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92024(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-20 Application filed by Novartis Ag filed Critical Novartis Ag

2012-08-20 Publication of LU92024I2 publication Critical patent/LU92024I2/fr

Links

VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 title 1
229960005415 pasireotide Drugs 0.000 title 1
108700017947 pasireotide Proteins 0.000 title 1
NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 title 1
229940050423 signifor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Oncology (AREA)

LU92024C 2000-08-01 2012-06-20 Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR) LU92024I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0018891.2A GB0018891D0 (en)	2000-08-01	2000-08-01	Organic compounds
PCT/EP2001/008824 WO2002010192A2 (fr)	2000-08-01	2001-07-30	Analogues de somatostatine

Publications (1)

Publication Number	Publication Date
LU92024I2 true LU92024I2 (fr)	2012-08-20

Family

ID=9896782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92024C LU92024I2 (fr)	2000-08-01	2012-06-20	Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)

Country Status (35)

Country	Link
US (5)	US7473761B2 (fr)
EP (1)	EP1307486B1 (fr)
JP (1)	JP3829118B2 (fr)
KR (2)	KR100799394B1 (fr)
CN (1)	CN1267451C (fr)
AR (1)	AR034132A1 (fr)
AT (1)	ATE393782T1 (fr)
AU (2)	AU8977801A (fr)
BE (1)	BE2012C026I2 (fr)
BR (1)	BRPI0112859B8 (fr)
CA (1)	CA2416293C (fr)
CY (2)	CY1108547T1 (fr)
CZ (1)	CZ302461B6 (fr)
DE (1)	DE60133823T2 (fr)
DK (1)	DK1307486T3 (fr)
EC (1)	ECSP034456A (fr)
ES (1)	ES2305104T3 (fr)
FR (1)	FR12C0041I2 (fr)
GB (1)	GB0018891D0 (fr)
HU (1)	HU227812B1 (fr)
IL (2)	IL153920A0 (fr)
LU (1)	LU92024I2 (fr)
MX (1)	MXPA03000991A (fr)
MY (1)	MY138074A (fr)
NO (2)	NO331093B1 (fr)
NZ (1)	NZ523836A (fr)
PE (1)	PE20020176A1 (fr)
PL (1)	PL204161B1 (fr)
PT (1)	PT1307486E (fr)
RU (1)	RU2287533C2 (fr)
SI (1)	SI1307486T1 (fr)
SK (1)	SK287798B6 (fr)
TW (1)	TWI282341B (fr)
WO (1)	WO2002010192A2 (fr)
ZA (1)	ZA200300406B (fr)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
US7189856B2 (en)	2001-12-28	2007-03-13	Gideon Shapiro	Non-peptide somatostatin receptor ligands
GB0229020D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic compounds
JP4796303B2 (ja) *	2002-12-12	2011-10-19	ノバルティスアーゲー	４−ヒドロキシ−プロリン部分構造を含むペプチドの合成方法
GB0300095D0 (en) *	2003-01-03	2003-02-05	Novartis Ag	Organic compounds
GB0314695D0 (en) *	2003-06-24	2003-07-30	Novartis Ag	Organic compounds
AR044852A1 (es) *	2003-06-24	2005-10-05	Novartis Ag	Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0318682D0 (en) *	2003-08-08	2003-09-10	Novartis Ag	Organic compounds
EP1522311A1 (fr) *	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
GB0412866D0 (en) *	2004-06-09	2004-07-14	Novartis Ag	Organic compounds
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
GB0602639D0 (en)	2006-02-09	2006-03-22	Novartis Ag	Organic compounds
JP2009539803A (ja) *	2006-06-08	2009-11-19	ノバルティスアクチエンゲゼルシャフト	ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤
US7697338B2 (en) *	2006-11-16	2010-04-13	Sandisk Corporation	Systems for controlled boosting in non-volatile memory soft programming
WO2008064570A1 (fr) *	2006-11-28	2008-06-05	The University Of Hong Kong	Utilisation d'anticorps dirigés contre le précurseur de la granuline-épithéline (gep) dans la détection et la suppression du carcinome hépatocellulaire (hcc)
EP1941902A1 (fr) *	2007-01-02	2008-07-09	Novartis AG	Utilisation d' analogues de somatostatin pour le traitment de chéphalée vasculaire de horton
WO2008095063A1 (fr)	2007-01-31	2008-08-07	Dana-Farber Cancer Institute, Inc.	Peptides p53 stabilisés et utilisations de ceux-ci
EP2508531B1 (fr)	2007-03-28	2016-10-19	President and Fellows of Harvard College	Polypeptides piqués
PE20090387A1 (es)	2007-05-24	2009-04-28	Novartis Ag	Formulacion de pasireotida
WO2009009035A1 (fr) *	2007-07-06	2009-01-15	Ipsen Pharma S.A.S.	Analogue de la somatostatine et ses utilisations
GB0719818D0 (en) *	2007-10-11	2007-11-21	Asterion Ltd	Growth hormone fusion polypeptides
PT2224947E (pt)	2007-11-28	2015-06-24	Novartis Ag	Utilização de análogos de somatostatina em meningioma
PL2225271T3 (pl)	2007-12-03	2013-12-31	Italfarmaco Spa	Nowe nieselektywne analogi somatostatyny
EP2067786A1 (fr)	2007-12-07	2009-06-10	ITALFARMACO S.p.A.	Nouveaux analogues non sélectifs de somatostatine
US20090325863A1 (en) *	2008-06-13	2009-12-31	Kleinberg David L	Somatostatin analogs and IGF-I inhibition for breast cancer prevention
SI2310042T1 (sl) *	2008-07-08	2013-03-29	Novartis Ag	Uporaba pasireotida za zdravljenje endogene hiperinzulinemične hipoglikemije
EP2213307A1 (fr)	2009-02-03	2010-08-04	Novartis AG	Formulations de dépôt injectables
EP2172189A1 (fr)	2008-10-01	2010-04-07	Novartis AG	Compositions pharmaceutiques
BRPI0918652B1 (pt)	2008-09-17	2021-10-19	Chiasma, Inc.	Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
UY33236A (es)	2010-02-25	2011-09-30	Novartis Ag	Inhibidores dimericos de las iap
CN103282510A (zh)	2010-08-13	2013-09-04	爱勒让治疗公司	拟肽大环化合物
WO2012074559A2 (fr)	2010-12-02	2012-06-07	New York University	Traitement d'une maladie kystique non proliférative
UY33794A (es)	2010-12-13	2012-07-31	Novartis Ag	Inhibidores diméricos de las iap
US20130266590A1 (en)	2010-12-13	2013-10-10	Novartis Ag	Dimeric iap inhibitors
US20130035054A1 (en) *	2011-07-14	2013-02-07	Faceon Mobile	Phone with multi-portal access for display during incoming and outgoing call
US8835123B2 (en)	2011-08-02	2014-09-16	New York University	Methods for detecting progenitor cells and uses thereof
JP6026544B2 (ja)	2011-09-27	2016-11-16	ノバルティスアーゲー	変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
KR20140100937A (ko)	2011-10-18	2014-08-18	에일러론 테라퓨틱스 인코포레이티드	펩티도미메틱 거대고리
CN104105479B (zh)	2011-12-05	2018-04-10	卡穆鲁斯公司	鲁棒性控释制剂
KR20140098242A (ko)	2011-12-05	2014-08-07	노파르티스 아게	안드로겐 수용체 길항제로서의 시클릭 우레아 유도체
AU2013208720A1 (en)	2012-01-09	2014-07-24	Arrowhead Research Corporation	RNAi agents to treat Beta-Catenin related diseases
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
WO2013123266A1 (fr)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Macrocycles peptidomimétiques
JP6450192B2 (ja)	2012-02-15	2019-01-09	エイルロンセラピューティクス，インコーポレイテッド	トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
SG11201407678YA (en) *	2012-05-25	2014-12-30	Camurus Ab	Somatostatin receptor agonist formulations
TWI633887B (zh) *	2012-05-31	2018-09-01	大塚製藥股份有限公司	用於預防及／或治療多囊性腎臟病之藥物
WO2014071241A1 (fr)	2012-11-01	2014-05-08	Aileron Therapeutics, Inc.	Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci
US9480759B2 (en)	2012-11-21	2016-11-01	Serene, Llc	Tin-117m somatostatin receptor binding compounds and methods
EP3360870A1 (fr)	2013-02-19	2018-08-15	Novartis AG	Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des estrogènes
MX355945B (es)	2013-03-14	2018-05-07	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
BR112015022483A2 (pt)	2013-03-14	2017-07-18	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (fr)	2013-03-22	2014-09-25	Novartis Ag	1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
CN103467575B (zh) *	2013-08-22	2016-03-02	深圳翰宇药业股份有限公司	一种帕西瑞肽的制备方法
CN103641894B (zh) *	2013-12-06	2015-10-28	深圳翰宇药业股份有限公司	一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (fr)	2013-12-16	2015-06-25	Novartis Ag	Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
CN105828803B (zh)	2013-12-19	2019-06-07	诺华股份有限公司	药物递送系统
CN105899493B (zh)	2014-01-17	2019-03-29	诺华股份有限公司	用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (fr)	2014-01-17	2018-08-22	Novartis AG	Dérivés de 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine et compositions les contenant pour l'inhibition de l'activité de shp2
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en)	2014-03-14	2023-12-06	Immutep Sas	Antibody molecules to lag-3 and uses thereof
CA2947939A1 (fr)	2014-05-28	2015-12-03	Idenix Pharmaceuticals Llc	Derives de nucleosides pour le traitement du cancer
SG11201702223UA (en)	2014-09-24	2017-04-27	Aileron Therapeutics Inc	Peptidomimetic macrocycles and uses thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (fr)	2014-10-14	2024-01-30	Novartis Ag	Molecules d'anticorps de pd-l1 et leurs utilisations
WO2016089833A1 (fr)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Nouveaux composés tricycliques comme inhibiteurs d'enzymes idh mutantes
WO2016089830A1 (fr)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Nouveaux composés tricycliques utilisés en tant qu'inhibiteurs d'enzymes idh mutantes
WO2016089797A1 (fr)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Composés tricycliques innovants servant d'inhibiteurs d'enzymes idh mutantes
EP4321213A3 (fr)	2014-12-10	2024-05-15	Amryt Endo, Inc.	Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
WO2016100882A1 (fr)	2014-12-19	2016-06-23	Novartis Ag	Polythérapies
EP3233899B1 (fr)	2014-12-19	2020-06-24	Auro Peptides LTD	Procédé de préparation de pasiréotide
HUE071943T2 (hu)	2015-02-03	2025-10-28	Amryt Endo Inc	Akromegália kezelése oktreotid orális alkalmazásával
HK1248603A1 (zh)	2015-03-10	2018-10-19	Aduro Biotech, Inc.	用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
US10253067B2 (en)	2015-03-20	2019-04-09	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
WO2016162127A1 (fr) *	2015-04-08	2016-10-13	Polyphor Ag	Peptidomimétiques à squelette cyclisé
WO2016189055A1 (fr)	2015-05-27	2016-12-01	Idenix Pharmaceuticals Llc	Nucléotides pour le traitement du cancer
WO2016203405A1 (fr)	2015-06-19	2016-12-22	Novartis Ag	Composés et compositions pour inhiber l'activité de shp2
US10287266B2 (en)	2015-06-19	2019-05-14	Novartis Ag	Compounds and compositions for inhibiting the activity of SHP2
WO2016203404A1 (fr)	2015-06-19	2016-12-22	Novartis Ag	Composés et compositions pour inhiber l'activité de shp2
US10556924B2 (en)	2015-06-22	2020-02-11	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of pasireotide
GB201511790D0 (en)	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (fr)	2015-07-29	2017-02-02	Novartis Ag	Polythérapies comprenant des molécules d'anticorps contre tim -3
EP4378957A3 (fr)	2015-07-29	2024-08-07	Novartis AG	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US11453697B1 (en)	2015-08-13	2022-09-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
SG10202010609QA (en)	2015-08-13	2020-11-27	Merck Sharp & Dohme	Cyclic di-nucleotide compounds as sting agonists
JP2019500893A (ja)	2015-11-03	2019-01-17	ヤンセンバイオテツク，インコーポレーテツド	Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
WO2017106062A1 (fr)	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
KR102833068B1 (ko)	2015-12-17	2025-07-14	노파르티스 아게	Pd-1에 대한 항체 분자 및 그의 용도
CN109415343A (zh)	2016-05-04	2019-03-01	基因科学医药公司	用于治疗增殖性疾病的取代的2,4-二氨基-喹啉衍生物
KR102457146B1 (ko)	2016-06-14	2022-10-19	노파르티스 아게	Shp2의 활성을 억제하기 위한 화합물 및 조성물
EP3507367A4 (fr)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
MA46452B1 (fr)	2016-10-04	2021-10-29	Merck Sharp & Dohme	Composés de benzo[b]thiophéne en tant qu'agonistes de sting
EP3541825A1 (fr)	2016-11-21	2019-09-25	Idenix Pharmaceuticals LLC.	Dérivés de nucléosides cycliques à substitution phosphate pour le traitement de maladies hépatiques
JP7275031B2 (ja)	2017-01-27	2023-05-17	ヤンセンバイオテツク，インコーポレーテツド	Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
CN110234404A (zh)	2017-01-27	2019-09-13	詹森生物科技公司	作为sting激动剂的环状二核苷酸
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3621624B1 (fr)	2017-05-12	2023-08-30	Merck Sharp & Dohme LLC	Composés dinucléotidiques cycliques en tant qu'agonistes sting
WO2018237173A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
AU2018311965A1 (en)	2017-08-04	2020-02-13	Merck Sharp & Dohme Llc	Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CA3071538A1 (fr)	2017-08-04	2019-02-07	Merck Sharp & Dohme Corp.	Agonistes benzo[b]thiophene de sting pour le traitement du cancer
US10435389B2 (en)	2017-09-11	2019-10-08	Krouzon Pharmaccuticals, Inc.	Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
WO2019067332A1 (fr)	2017-09-27	2019-04-04	Merck Sharp & Dohme Corp.	Compositions et procédés de traitement du cancer par une combinaison d'anticorps anti-récepteur de mort programmée (pd-1) et d'un antagoniste de cxcr2
WO2019078968A2 (fr) *	2017-10-18	2019-04-25	Angex Pharmaceutical, Inc.	Composés cycliques en tant qu'agents immunomodulateurs
US12275729B2 (en)	2017-11-01	2025-04-15	Merck Sharp & Dohme Llc	Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
ES2948307T3 (es)	2017-11-14	2023-09-08	Merck Sharp & Dohme Llc	Nuevos compuestos de biarilo sustituidos como inhibidores de indolamina 2,3-dioxigenasa (IDO)
US11498904B2 (en)	2017-11-14	2022-11-15	Merck Sharp & Dohme Llc	Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
MX2020006290A (es)	2017-12-15	2020-12-03	Janssen Biotech Inc	Dinucleotidos ciclicos como agonistas de sting.
US11685761B2 (en)	2017-12-20	2023-06-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12215116B2 (en)	2018-03-13	2025-02-04	Merck Sharp & Dohme Llc	Arginase inhibitors and methods of use
WO2019195063A1 (fr)	2018-04-03	2019-10-10	Merck Sharp & Dohme Corp.	Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting
KR102755259B1 (ko)	2018-04-03	2025-01-15	머크 샤프 앤드 돔 엘엘씨	Sting 효능제로서의 벤조티오펜 및 관련 화합물
US11542505B1 (en)	2018-04-20	2023-01-03	Merck Sharp & Dohme Llc	Substituted RIG-I agonists: compositions and methods thereof
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3810116B1 (fr)	2018-05-31	2023-11-15	Merck Sharp & Dohme LLC	Nouveaux composés [1,1,1]bicyclo substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
US11274111B2 (en)	2018-06-20	2022-03-15	Merck Sharp & Dohme Corp.	Arginase inhibitors and methods of use
TW202517302A (zh)	2018-07-25	2025-05-01	法商高級催化劑應用品有限公司	穩定的、濃縮的放射性核種錯合物溶液
US10596276B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
US10596278B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
TWI827677B (zh)	2018-09-18	2024-01-01	美商尼坎醫療公司	作為src同源-2磷酸酶抑制劑之稠合三環衍生物
KR20210137422A (ko)	2018-09-25	2021-11-17	블랙 다이아몬드 테라퓨틱스, 인코포레이티드	티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
US20220041613A1 (en)	2018-09-25	2022-02-10	Black Diamond Therapeutics, Inc.	Tyrosine kinase inhibitor compositions, methods of making and methods of use
CA3113379A1 (fr)	2018-09-29	2020-04-02	Novartis Ag	Procede de fabrication d'un compose pour inhiber l'activite de shp2
EP3873464B1 (fr)	2018-11-01	2025-07-30	Merck Sharp & Dohme LLC	Nouveaux composés pyrazole substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
EP3877366B1 (fr)	2018-11-06	2026-01-28	Merck Sharp & Dohme LLC	Nouveaux composés tricycliques substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
EP3886845B1 (fr)	2018-11-28	2024-09-04	Merck Sharp & Dohme LLC	Nouveaux composés de piperazine amide substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
WO2020131598A1 (fr)	2018-12-18	2020-06-25	Merck Sharp & Dohme Corp.	Inhibiteurs d'arginase et procédés d'utilisation
EP3946324B1 (fr)	2019-04-04	2025-07-30	Merck Sharp & Dohme LLC	Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète
EP3990635A1 (fr)	2019-06-27	2022-05-04	Rigontec GmbH	Procédé de conception pour ligands rig-i optimisés
JP2022543086A (ja)	2019-08-02	2022-10-07	メルサナセラピューティクスインコーポレイテッド	がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
KR102910319B1 (ko)	2019-08-15	2026-01-09	블랙 다이아몬드 테라퓨틱스, 인코포레이티드	알키닐 퀴나졸린 화합물
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
PH12022551030A1 (en)	2019-10-28	2023-04-24	Shanghai Inst Materia Medica Cas	Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
US20230074558A1 (en)	2019-12-06	2023-03-09	Mersana Therapeutics, Inc.	Dimeric compounds as sting agonists
US20220396577A1 (en)	2019-12-17	2022-12-15	Merck Sharp & Dohme Llc	Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
WO2021141751A1 (fr)	2020-01-07	2021-07-15	Merck Sharp & Dohme Corp.	Inhibiteurs d'arginase et méthodes d'utilisation
WO2021195206A1 (fr)	2020-03-24	2021-09-30	Black Diamond Therapeutics, Inc.	Formes polymorphes et utilisations associées
JP2023520513A (ja)	2020-04-02	2023-05-17	メルサナセラピューティクスインコーポレイテッド	Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート
IL297781A (en)	2020-05-06	2022-12-01	Merck Sharp & Dohme Llc	il4i1 inhibitors and methods of use
EP4267575A1 (fr)	2020-12-22	2023-11-01	Nikang Therapeutics, Inc.	Composés pour la dégradation de la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie de l'ubiquitine-protéosome
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
JP2024504932A (ja)	2021-01-13	2024-02-02	モンテローザセラピューティクス，インコーポレイテッド	イソインドリノン化合物
WO2022170052A1 (fr)	2021-02-05	2022-08-11	Black Diamond Therapeutics, Inc.	Dérivés de quinazoline, dérivés de pyridopyrimidine, dérivés de pyrimidopyrimidine et leurs utilisations
EP4323350A1 (fr)	2021-04-14	2024-02-21	Monte Rosa Therapeutics AG	Composés d'iso-indolinone
WO2022219412A1 (fr)	2021-04-14	2022-10-20	Monte Rosa Therapeutics Ag	Composés amide d'isoindolinone utilisés pour traiter des maladies associées à gspt1
WO2022227015A1 (fr)	2021-04-30	2022-11-03	Merck Sharp & Dohme Corp.	Inhibiteurs d'il4i1 et méthodes d'utilisation
TW202317589A (zh)	2021-07-14	2023-05-01	美商尼坎醫療公司	作為ｋｒａｓ抑制劑的伸烷基衍生物
KR20240167846A (ko)	2022-03-28	2024-11-28	니캉 테라퓨틱스 인코포레이티드	사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
WO2023240024A1 (fr)	2022-06-08	2023-12-14	Nikang Therapeutics, Inc.	Dérivés de sulfamide utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline
JP2025528439A (ja) *	2022-08-30	2025-08-28	グラフトンセラピューティクスエスアエールエル	複数のソマトスタチン受容体サブタイプ選択性を有するハロゲン化ソマトスタチン類似体
JP2025537123A (ja)	2022-11-11	2025-11-14	ニカングセラピューティクス，インコーポレイテッド	ユビキチンプロテアソーム経路を介してサイクリン依存性キナーゼ２を分解するための２，５－置換ピリミジン誘導体を含有する二官能性化合物
WO2024206357A1 (fr)	2023-03-29	2024-10-03	Merck Sharp & Dohme Llc	Inhibiteurs d'il4i1 et procédés d'utilisation
TW202502382A (zh)	2023-06-30	2025-01-16	美商默沙東有限責任公司	治療組合及其用途和治療方法
WO2025072462A1 (fr)	2023-09-27	2025-04-03	Nikang Therapeutics, Inc.	Dérivés sulfonamides utilisés en tant qu'inhibiteurs de la kinase 2 dépendante de la cycline
WO2025117616A1 (fr)	2023-11-27	2025-06-05	Nikang Therapeutics, Inc.	Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase cycline-dépendante 2 et la kinase cycline-dépendante 4 par l'intermédiaire de la voie ubiquitine-protéasome
WO2025117981A1 (fr)	2023-12-02	2025-06-05	Nikang Therapeutics, Inc.	Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante de la cycline par l'intermédiaire d'un système ubiquitine/protéasome
WO2025212828A1 (fr)	2024-04-03	2025-10-09	Nikang Therapeutics, Inc.	Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase cycline-dépendante 2 et la kinase cycline-dépendante 4 par l'intermédiaire de la voie ubiquitine-protéasome
WO2025240536A1 (fr)	2024-05-15	2025-11-20	Nikang Therapeutics, Inc.	Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante d'une cycline et/ou la kinase 4 dépendante d'une cycline par l'intermédiaire de la voie ubiquitine-protéasome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3863008A (en)	1973-06-11	1975-01-28	American Home Prod	Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) *	1979-10-31	1984-10-19	Merck & Co Inc	Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en)	1980-07-09	1981-10-06	E. R. Squibb & Sons, Inc.	Lyophilized hydrocolloio foam
US4612386A (en) *	1980-09-16	1986-09-16	The Dow Chemical Company	Process for making esters
US4505897A (en)	1983-04-18	1985-03-19	The Administrators Of The Tulane Educational Fund	Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en)	1985-06-17	1986-09-16	Merck & Co., Inc.	Cyclic hexapeptide somatostatin analogs
CA2012115C (fr)	1989-03-15	2001-07-03	Biomeasure, Inc.	Somatostatines iodees
WO1990012811A1 (fr)	1989-04-26	1990-11-01	The Administrators Of The Tulane Educational Fund	Analogues lineaires de somatostatine
US5716596A (en)	1992-06-23	1998-02-10	Diatide, Inc.	Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
CA2167281C (fr)	1993-07-15	2001-09-04	Richard T. Dean	Peptides radiomarques, derives de la somatostatine, pour visualisation et applications therapeutiques
SI0788509T1 (en)	1993-08-09	2003-10-31	Societe De Conseils De Recherches	Therapeutic peptide derivatives
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
GB9513224D0 (en) *	1995-06-29	1995-09-06	Sandoz Ltd	Organic compounds
IT1277391B1 (it)	1995-07-28	1997-11-10	Romano Deghenghi	Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
EP0912551A1 (fr)	1996-05-14	1999-05-06	Novo Nordisk A/S	Agonistes et antagonistes de la somatostatine
US6355613B1 (en)	1996-07-31	2002-03-12	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (fr)	1998-09-01	2000-03-01	Alison Buchan	Traitement de l'endothelium avec des analogues de la somatostatine
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds

2000
- 2000-08-01 GB GBGB0018891.2A patent/GB0018891D0/en not_active Ceased
2001
- 2001-07-26 TW TW090118314A patent/TWI282341B/zh active
- 2001-07-26 PE PE2001000760A patent/PE20020176A1/es active IP Right Grant
- 2001-07-30 KR KR1020067005526A patent/KR100799394B1/ko not_active Expired - Lifetime
- 2001-07-30 WO PCT/EP2001/008824 patent/WO2002010192A2/fr not_active Ceased
- 2001-07-30 US US10/343,288 patent/US7473761B2/en active Active
- 2001-07-30 SI SI200130836T patent/SI1307486T1/sl unknown
- 2001-07-30 EP EP01969555A patent/EP1307486B1/fr not_active Expired - Lifetime
- 2001-07-30 BR BRPI0112859A patent/BRPI0112859B8/pt not_active IP Right Cessation
- 2001-07-30 SK SK121-2003A patent/SK287798B6/sk not_active IP Right Cessation
- 2001-07-30 AT AT01969555T patent/ATE393782T1/de active
- 2001-07-30 MY MYPI20013578A patent/MY138074A/en unknown
- 2001-07-30 DK DK01969555T patent/DK1307486T3/da active
- 2001-07-30 IL IL15392001A patent/IL153920A0/xx unknown
- 2001-07-30 AU AU8977801A patent/AU8977801A/xx active Pending
- 2001-07-30 MX MXPA03000991A patent/MXPA03000991A/es active IP Right Grant
- 2001-07-30 PL PL358718A patent/PL204161B1/pl unknown
- 2001-07-30 CN CNB018136869A patent/CN1267451C/zh not_active Expired - Lifetime
- 2001-07-30 CA CA2416293A patent/CA2416293C/fr not_active Expired - Lifetime
- 2001-07-30 HU HU0300684A patent/HU227812B1/hu active Protection Beyond IP Right Term
- 2001-07-30 AU AU2001289778A patent/AU2001289778B2/en active Active
- 2001-07-30 KR KR10-2003-7001435A patent/KR20030033008A/ko not_active Ceased
- 2001-07-30 NZ NZ523836A patent/NZ523836A/en not_active IP Right Cessation
- 2001-07-30 DE DE60133823T patent/DE60133823T2/de not_active Expired - Lifetime
- 2001-07-30 AR ARP010103642A patent/AR034132A1/es active IP Right Grant
- 2001-07-30 JP JP2002515921A patent/JP3829118B2/ja not_active Expired - Lifetime
- 2001-07-30 PT PT01969555T patent/PT1307486E/pt unknown
- 2001-07-30 CZ CZ20030288A patent/CZ302461B6/cs unknown
- 2001-07-30 RU RU2003105817/04A patent/RU2287533C2/ru active Protection Beyond IP Right Term
- 2001-07-30 ES ES01969555T patent/ES2305104T3/es not_active Expired - Lifetime
2003
- 2003-01-13 IL IL153920A patent/IL153920A/en active Protection Beyond IP Right Term
- 2003-01-15 ZA ZA200300406A patent/ZA200300406B/xx unknown
- 2003-01-29 EC EC2003004456A patent/ECSP034456A/es unknown
- 2003-01-30 NO NO20030484A patent/NO331093B1/no not_active IP Right Cessation
2008
- 2008-07-29 CY CY20081100789T patent/CY1108547T1/el unknown
- 2008-11-05 US US12/265,135 patent/US7939625B2/en not_active Expired - Fee Related
2011
- 2011-03-16 US US13/048,935 patent/US9035021B2/en not_active Expired - Lifetime
- 2011-03-16 US US13/048,932 patent/US8822637B2/en not_active Expired - Lifetime
2012
- 2012-06-20 LU LU92024C patent/LU92024I2/fr unknown
- 2012-06-21 BE BE2012C026C patent/BE2012C026I2/fr unknown
- 2012-06-26 FR FR12C0041C patent/FR12C0041I2/fr active Active
- 2012-06-29 NO NO2012012C patent/NO2012012I2/no not_active IP Right Cessation
- 2012-06-29 CY CY2012018C patent/CY2012018I2/el unknown
2015
- 2015-04-08 US US14/681,226 patent/US20150218223A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110166320A1 (en)	2011-07-07
DK1307486T3 (da)	2008-08-25
KR100799394B1 (ko)	2008-01-30
WO2002010192A3 (fr)	2002-09-19
US20110172157A1 (en)	2011-07-14
CN1267451C (zh)	2006-08-02
HK1057051A1 (en)	2004-03-12
DE60133823T2 (de)	2009-05-20
PL204161B1 (pl)	2009-12-31
ES2305104T3 (es)	2008-11-01
CY2012018I1 (el)	2015-10-07
RU2287533C2 (ru)	2006-11-20
NO2012012I2 (no)	2012-07-30
CA2416293A1 (fr)	2002-02-07
CY2012018I2 (el)	2015-10-07
DE60133823D1 (de)	2008-06-12
NO20030484D0 (no)	2003-01-30
US7939625B2 (en)	2011-05-10
MXPA03000991A (es)	2003-06-09
BRPI0112859B8 (pt)	2021-05-25
ZA200300406B (en)	2004-04-02
CZ302461B6 (cs)	2011-06-01
BRPI0112859B1 (pt)	2016-03-01
IL153920A (en)	2010-12-30
AU8977801A (en)	2002-02-13
HUP0300684A3 (en)	2004-08-30
US20090069225A1 (en)	2009-03-12
AR034132A1 (es)	2004-02-04
BE2012C026I2 (fr)	2020-12-15
SI1307486T1 (sl)	2008-08-31
PL358718A1 (en)	2004-08-09
NO331093B1 (no)	2011-10-03
WO2002010192A2 (fr)	2002-02-07
KR20060035809A (ko)	2006-04-26
TWI282341B (en)	2007-06-11
NZ523836A (en)	2004-08-27
US7473761B2 (en)	2009-01-06
US9035021B2 (en)	2015-05-19
US20150218223A1 (en)	2015-08-06
BR0112859A (pt)	2003-07-01
SK1212003A3 (en)	2003-08-05
CY1108547T1 (el)	2014-04-09
PE20020176A1 (es)	2002-03-26
CN1446229A (zh)	2003-10-01
ATE393782T1 (de)	2008-05-15
EP1307486A2 (fr)	2003-05-07
CZ2003288A3 (cs)	2003-05-14
US8822637B2 (en)	2014-09-02
SK287798B6 (sk)	2011-10-04
IL153920A0 (en)	2003-07-31
WO2002010192A9 (fr)	2002-10-17
GB0018891D0 (en)	2000-09-20
NO20030484L (no)	2003-03-19
HUP0300684A2 (hu)	2003-09-29
JP3829118B2 (ja)	2006-10-04
PT1307486E (pt)	2008-07-31
FR12C0041I2 (fr)	2013-01-11
EP1307486B1 (fr)	2008-04-30
NO2012012I1 (no)	2012-06-29
MY138074A (en)	2009-04-30
US20050014686A1 (en)	2005-01-20
JP2004505095A (ja)	2004-02-19
AU2001289778B2 (en)	2005-02-03
CA2416293C (fr)	2011-05-10
HU227812B1 (hu)	2012-03-28
KR20030033008A (ko)	2003-04-26
FR12C0041I1 (fr)	2012-07-27
ECSP034456A (es)	2003-03-10

Publication	Publication Date	Title
LU92024I2 (fr)	2012-08-20	Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU92381I2 (fr)	2014-04-28	Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91624I2 (fr)	2010-01-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
LU92419I2 (fr)	2014-06-02	Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU91757I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU91673I2 (fr)	2010-06-07	"Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91269I2 (fr)	2006-09-26	Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
LU91346I2 (fr)	2007-09-11	Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU92745I2 (fr)	2015-08-17	Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU93093I2 (fr)	2016-08-01	Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU91122I2 (fr)	2005-01-10	Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
CY2013011I2 (el)	2015-08-05	Μεθοδος χορηγησης διφωσφονικων
LU92336I2 (fr)	2014-02-17	Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU91501I2 (fr)	2009-01-26	Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU91882I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91076I2 (fr)	2004-07-05	Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91138I2 (fr)	2005-04-04	Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU92871I2 (fr)	2016-01-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU91883I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
ATE253576T1 (de)	2003-11-15	8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
LU91189I2 (fr)	2005-10-03	Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)